feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

Gold prices reach record highs

trending

Harry Kane rescues Bayern draw

trending

Mbappé scores, Madrid beats Alaves

trending

Bangalore cold wave continues

trending

Railways plans for pay commission

trending

India vs South Africa live

trending

Heavy rain alert issued

trending

Mahindra XUV 7XO pre-booking

trending

Snapchat woos Indian advertisers

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Veterinary Sedative Fuels New Opioid Epidemic Nightmare

Veterinary Sedative Fuels New Opioid Epidemic Nightmare

15 Dec

•

Summary

  • Medetomidine, a vet sedative, causes severe withdrawal, overwhelming hospitals.
  • Drug supply in Philadelphia sees 91% fentanyl mix with medetomidine.
  • Hospital admissions for withdrawal surged over 160% in nine months.
Veterinary Sedative Fuels New Opioid Epidemic Nightmare

Philadelphia is grappling with a new drug crisis fueled by medetomidine, a potent veterinary sedative. This drug, now found in 91% of the city's fentanyl supply, causes severe and life-threatening withdrawal symptoms, including dangerously high blood pressure and heart rates, overwhelming local hospitals.

The consequences are dire, with hospital admissions for medetomidine withdrawal soaring by over 160% in the first nine months of 2025 compared to all of 2023. This situation strains emergency services and has led to intensive care units being overburdened, creating a distinct "withdrawal crisis."

Medetomidine's addictive nature and low cost make it attractive to drug dealers, and its impact is spreading to other states. The crisis highlights the evolving challenges of addiction, with withdrawal, not overdose, becoming the primary threat.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Medetomidine is a powerful veterinary sedative, not intended for human use, that has entered Philadelphia's drug supply. It causes severe withdrawal symptoms that are overwhelming hospitals.
Hospitals in Philadelphia have been strained by a surge in patients experiencing medetomidine withdrawal, leading to ICU overcrowding and an increase in critical care needs.
Withdrawal from medetomidine can cause catastrophically high heart rates and blood pressure, tremors, uncontrollable vomiting, and in severe cases, require intensive care.

Read more news on

Healthside-arrow

You may also like

PSY Under Investigation for Prescription Drug Allegations

12 Dec • 23 reads

article image

FDA Proposes Catch-Up for US Sunscreen Standards

12 Dec • 23 reads

article image

Belfast Man's Painkiller Addiction Leads to Surgery

8 Dec • 53 reads

article image

Deadly Animal Drug Surges in UK Street Ketamine

4 Dec • 89 reads

article image

Perry's Fatal Ketamine Overdose: A Medical Mystery

3 Dec • 72 reads